Latest Tokyo Brief coverage on Shionogi & Co.,Ltd., tracking filings, financial news, and market signals from Japan.
TSE:4507
Shionogi will buy all of US rare-disease drugmaker IntraBio for $2bn, taking worldwide rights to AQNEURSA, which won a first-of-its-kind ataxia-telangiectasia approval on 18 September; closing is targeted for November or December, subject to clearances.
SUSMED began selling its Medcle insomnia app on 1 June, but the year to June 2026 rested on ¥340mn of partner milestones, ended with a ¥382.7mn net loss, and the annual report gives no sales figures for the app.
Shionogi's amended securities report lowers disclosed compensation for its senior directors to ¥642mn from ¥895mn, driven by a corrected fringe-benefit figure for foreign-national directors; the correction also revises a related-party pay note but leaves other financial-statement figures unchanged.
Shionogi and Torii Pharmaceutical secured Japanese approval to prescribe a 0.5% version of their non-steroid eczema cream to children under 12, backed by a trial in patients aged 2 to under 12 showing it beat plain vehicle cream over eight weeks with good long-term tolerability.
Shionogi cleared a Japanese approval adding a booster dose to its Omicron JN.1 COVID-19 vaccine, completing the technical groundwork for supplying future season-matched shots, but the approved formulation itself won't be sold because it doesn't match the strain designated for the 2026-2027 season.
A string of drugmaker acquisitions, not stronger underlying sales, pushed Shionogi's quarterly net profit up 148% to ¥97.7bn, covering most of its own first-half profit guidance within three months while cutting its cash pile by more than half.
Current holdings disclosed by tracked funds.